This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CT-011, MDV9300
Description: Pidilizumab (CT-011) is a humanized monoclonal antibody whose target is currently being determined. Pidilizumab modulates the immune response and inhibits tumor growth and the spread of metastases. Mechanistically, pidilizumab activity leads to extended survival of lymphocytes, primarily effector/memory T cells. Pidilizumab also augments anti-tumor activities of NK cells. The enhanced activities of T and NK cells are translated into the intensification of anti-tumor immune response and the generation of tumor-specific memory cells.
Curetech and Teva
In May 2006, Curetech and Teva finalized a collaboration agreement. Under this agreement, Teva Pharmaceuticals invested in CureTech an initial amount of $6 million. These funds will support the ongoing clinical development of CT-011. The agreement stipulates that given certain conditions, Teva will have an option to further invest in CureTech up to $25 million to support further development of CT-011 antibody for the planned clinical indications.
In January 2013, Teva announced the termination of its collaboration with CureTech.
Curetech and Medivation
In October 2014, Medivation announced Medivation has licensed exclusive worldwide rights to CureTech's late-stage clinical molecule pidilizumab (CT-011). Under the license agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including oncology.
The arrangement with CureTech also...See full deal structure in Biomedtracker
Partners: CureTech, Ltd.
Additional information available to subscribers only: